TREATMENT OF PRIMARY AND/OR SECONDARY LUNG TUMORS USING GASEOUS NITRIC OXIDE INHALATION
Described herein are methods of inhibiting growth of cells or tissue of a primary and/or secondary tumor in a respiratory tract of a subject in need thereof and/or sensitizing cells or tissue of a primary and/or secondary tumor in a respiratory tract of the subject to an anti-cancer therapy. The methods are effected by administering gaseous nitric oxide (gNO) via inhalation at a concentration in a range of from about 1 ppm to about 1,000 ppm. The gNO may be co-administered with an anti-cancer therapy and/or an agent suitable for treating methemoglobinemia.
1 . A method of inhibiting growth of cells or tissue of a primary and/or secondary tumor in a respiratory tract of a subject in need thereof, the method comprising administering to the subject gaseous nitric oxide (gNO) via inhalation for at least 1 second per day, wherein a concentration of gNO is in a range of from about 1 ppm to about 1,000 ppm.
2 . The method of claim 1 , wherein said concentration of gNO is in a range of from about 10 ppm to about 600 ppm.
3 . The method of claim 1 , comprising administering gNO for at least 10 minutes per day.
4 . The method of claim 1 , comprising administering gNO for no more than about 600 minutes per day.
5 . The method of claim 1 , wherein said gNO is mixed with a carrier gas, and a volumetric flow of said gNO mixed with said carrier gas is from about 1 liter per minute to about 100 liters per minute.
6 . The method of claim 1 , being effected for a time period in a range of from 1 to 100 days.
7 . The method of claim 1 , comprising administering gNO from 1 to 4 times per day.
8 . The method of claim 1 , wherein a product of said concentration of gNO and a daily time of inhalation of gNO is in a range of from about 0.0027 ppm·hour to about 6000 ppm·hour.
9 . The method of claim 1 , further comprising co-administering to the subject an anti-cancer therapy.
10 . The method of claim 9 , wherein said anti-cancer therapy is selected from the group consisting of a chemotherapeutic agent, an immune-oncological agent, and a radiation treatment.
11 . The method of claim 9 , wherein said anti-cancer therapy is administered at a sub-therapeutic dosage.
12 . The method of claim 1 , wherein said primary and/or secondary tumor in a respiratory tract is a lung cancer tumor and/or a lung metastasis.
13 . The method of claim 1 , further comprising administering an agent suitable for treating methemoglobinemia.
14 - 25 . (canceled)
26 . A method of sensitizing cells or tissue of a primary and/or secondary tumor in a respiratory tract of a subject in need thereof to an anti-cancer therapy, the method comprising co-administering to the subject the anti-cancer therapy and gaseous nitric oxide (gNO), said gNO being administered via inhalation for at least 1 second per day, wherein a concentration of gNO is in a range of from about 1 ppm to about 1,000 ppm.
27 . The method of claim 26 , wherein said concentration of gNO is in a range of from about 10 ppm to about 600 ppm.
28 . The method of claim 26 , comprising administering gNO for at least 10 minutes per day.
29 . The method of claim 26 , comprising administering gNO for no more than about 600 minutes per day.
30 . The method of claim 26 , wherein said gNO mixed is mixed with a carrier gas, and a volumetric flow of said gNO mixed with said carrier gas is from about 1 liter per minute to about 100 liters per minute.
31 . The method of claim 26 , comprising administering gNO for a time period in a range of from 1 to 100 days.
32 . The method of claim 26 , comprising administering gNO from 1 to 4 times per day.
33 . The method of claim 26 , wherein a product of said concentration of gNO and a daily time of inhalation of gNO is in a range of from about 0.0027 ppm·hour to about 6000 ppm·hour.
34 . The method of claim 26 , wherein said anti-cancer therapy is selected from the group consisting of a chemotherapeutic agent, an immune-oncological agent, and a radiation treatment.
35 . The method of claim 26 , wherein said primary and/or secondary tumor in a respiratory tract is a lung cancer tumor and/or a lung metastasis.
36 . The method of claim 26 , further comprising administering an agent suitable for treating methemoglobinemia.
37 . (canceled)